Unknown

Dataset Information

Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.


ABSTRACT:

Background

Rituximab (RTX) has recently been introduced as a second-line therapy for nephrotic syndrome in children. Studies show that RTX given during the nephrotic state may be less effective than treatment during a non-nephrotic state, possibly due to loss of RTX in the urine.

Case-diagnosis/treatment

We describe a 10-year-old boy with steroid-resistant nephrotic syndrome (SRNS) treated with RTX during a phase of active non-selective proteinuria. The serum half-life of RTX in this patient was less than 1 day compared to 20 days in patients without protein losses. Urinary clearance was at least 25 %, compared to approximately 0 % in control patients. However, RTX loss in the urine, as well as in pleural effusion and ascites, only partly explains the rapid drop in the serum

SUBMITTER: Counsilman CE 

PROVIDER: S-EPMC4483248 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature